Sun, Nov 23, 2014, 11:14 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • left2rightdoor left2rightdoor May 15, 2013 12:33 AM Flag

    Results coming in 3rd qtr - good transcript discussion Allovectin, Astellas, herpes vaccine

    "The response rate of adjudication as I said was completed in May. The adjudication – adjudicative response to data will be locked in July and we expect the top-line results to be released in the third quarter. And we’ll blind – un-blind those results simultaneously I would remind everybody the investigators, who are adjudicating they are not the investigators. The people who are adjudicating the data we are doing in a blinded fashion nobody has access to the data in the third-party database in a blinded fashion. It wouldn’t be unblended till it’s actually transferred to Vical secured source. So, lookout for the results. We are pleased by how we have conducted the trial and we are looking for time lining the results in the third quarter of this year."

    Good discussion of Allovectin trial, notes they have a manufacturing facility, other people also using their technology platform, more trials to come. Overall encouraging discussion.
    Expect $5-7 bucks in run up to results, then if successful, $15-25, depending on other programs progress, ie Astellas and herpes virus vaccine. Some analysts had a $20 value with 25% chance of success, but that percentage is looking conservative. Singer is right on.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VICL
1.09-0.01(-0.91%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.